Search for dissertations about: "FVIII"

Showing result 1 - 5 of 12 swedish dissertations containing the word FVIII.

  1. 1. Exploring Anti-FVIII Antibodies in Haemophilia A - Role in In Vitro Haemostasis and Clinical Disease

    University dissertation from Department of Clinical Sciences, Lund University

    Author : Jenny Klintman; [2013]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; hemophilia A; inhibitors; non-neutralizing anti-FVIII antibodies; thrombin generation assay; ELISA;

    Abstract : Haemophilia A (HA) is caused by defective synthesis of coagulation factor VIII(FVIII), which has serious effects on haemostasis; joints being the most common site of bleeding. The development of FVIII replacements has improved the situation for patients with haemophilia such that chronic arthropathy can be prevented, and life expectancy and the quality of life have increased. READ MORE

  2. 2. Pharmacokinetic dosing of factor VIII and factor IX in prophylactic treatment of haemophilia

    University dissertation from Hospital Pharmacy, Malmö University Hospital, S-205 02 Malmö, Sweden

    Author : Maj Carlsson; [1997]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Haematology; Prophylaxis; Pharmacokinetics; Pharmaceutical service; Haemophilia B; Haemophilia A; Factor IX; Factor VIII; Drug distribution; Cost-effectiveness; Dosage; extracellular fluids; Hematologi; extracellulära vätskor;

    Abstract : The aim of the thesis was to increase cost-effectiveness in prophylactic treatment of haemophilia. Prophylaxis is effective to prevent bleedings and arthropathy, but the high cost limits its use. First, a new distribution system for clotting factor concentrates was implemented in Sweden to improve availability and reduce risks and costs. READ MORE

  3. 3. Pharmacometric Approaches to Improve Dose Individualization Methods in Hemophilia A

    University dissertation from Uppsala : Acta Universitatis Upsaliensis

    Author : João A. Abrantes; Mats Karlsson; Elisabet I. Nielsen; Siv Jönsson; Ron Mathôt; [2019]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Bayesian forecasting; coagulation factor VIII; dose adaptation; hemophilia haemophilia A; inter-occasion variability; NONMEM; pharmacodynamics; pharmacokinetics; pharmacometrics; therapeutic drug monitoring; Farmaceutisk vetenskap; Pharmaceutical Science;

    Abstract : Hemophilia A is a bleeding disorder caused by the lack of functional coagulation factor VIII (FVIII). The overall aim of this thesis was to improve dose individualization of FVIII replacement therapy in hemophilia A using pharmacometric approaches. READ MORE

  4. 4. Structural and functional studies of factor V in health and disease

    University dissertation from Mårten Steen, Dept of Clinical Chemistry, University hospital Malmö, 205 02 Malmö

    Author : Mårten Steen; [2003]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Klinisk kemi; Clinical chemistry; APC resistance and hemophilia; thrombosis; factor VIII; coagulation; factor V;

    Abstract : The homologous blood coagulation factors V (FV) and factor VIII (FVIII) are important at sites of vascular injury for the amplification of the clotting cascade. Activated FV (FVa) serves as a cofactor to the enzyme activated factor X (FXa) in the activation of prothrombin. This complex is called the prothrombinase complex. READ MORE


    University dissertation from Karin Knobe, Dept. of Pediatrics, University Hospital, Malmö, SE- 20502

    Author : Karin Knobe; [2003]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Haematology; inhibitors; mutations; Factor IX; Factor VIII; coagulation; hemophilia A and B; extracellular fluids; Hematologi; extracellulära vätskor;

    Abstract : The general objective of the research underlying this dissertation was to conduct clinical and basic scientific studies to further elucidate the hemophilia and the coagulation process, with the goal of improving the care of families with these disorders. More specific aims were to evaluate epidemiological, genetic, clinical, and biochemical aspects of the development of inhibitors (antibodies) against FVIII and FIX in Swedish patients with hemophilia A and B (papers I, II, and III). READ MORE